Background:
Nanostructured lipid carriers (NLCs) are in high demand in the existing pharmaceutical
domain due to its high versatility. It is the newer generation of lipid nanoparticulate systems having a solid
matrix and greater stability at room temperature.
Objective:
To review the evidence related to the current state of the art of the NLCs system and its drug delivery
perspectives to the brain.
Methods:
Scientific data search, review of the current state of the art and drug delivery perspectives to the brain
for NLCs were undertaken to assess the applicability of NLCs in the management of neurological disorders
through an intranasal route of drug administration
Results:
NLCs are designed to fulfill all the industrial needs like simple technology, low cost, scalability, and
quantifications. Biodegradable and biocompatible lipids and surfactants used for NLCs have rendered them acceptable
from regulatory perspectives as well. Apart from these, NLCs have unique properties of high drug payload,
modulation of drug release profile, minimum drug expulsion during storage, and incorporation in various
dosage forms like gel, creams, granules, pellets, powders for reconstitution and colloidal dispersion. Ease of surface-
modification of NLCs enhances targeting efficiency and reduces systemic toxicity by providing site-specific
delivery to the brain through the intranasal route of drug administration.
Conclusion:
The present review encompasses the in-depth discussion over the current state of the art of NLCs,
nose-to-brain drug delivery perspectives, and its theranostic application as useful tools for better management
of various neurological disorders. Further, pharmacokinetic consideration and toxicity concern is also discussed
specifically for the NLCs system exploited in nose-to-brain delivery.
DEVELOPMENT OF RIVASTIGMINE LOADED SELF ASSEMBLED NANOSTRUCTURES OF NONIONIC SURFACTANTS FOR BRAIN DELIVERY
